FDA approves Teligent’s triamcinolone acetonide ointment

SILVER SPRING, Md. — The Food and Drug Administration has approved Teligent Pharmaceuticals’ triamcinolone acetonide ointment (USP, 0.1%), the company announced Monday. 

 

The ointment is indicated to treat skin inflammation, itching, dryness and redness. According to IMS Health, the product has and estimated market size of $24 million. Teligent expects to launch the ointment in the second quarter of 2015, and it will be available in 15- and 80-gram tubes, as well as a one-pound jar.